2012
DOI: 10.3109/13697137.2011.635825
|View full text |Cite
|
Sign up to set email alerts
|

Future long-term trials of postmenopausal hormone replacement therapy – what is possible and what is the optimal protocol and regimen?

Abstract: The ideal long-term, randomized, placebo-controlled trial of hormone replacement therapy (HRT) from near menopause for up to 30 years to assess major morbidity and mortality is impractical because of high cost, participant retention, therapy compliance, and continuity of research staff and funding. Also the trial regimen may become outdated. It is nihilistic to demand such a long-term trial before endorsing HRT. However, medium-term trials using surrogate measures for long-term morbidity and mortality are poss… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2012
2012
2017
2017

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
references
References 32 publications
0
0
0
Order By: Relevance